Hypoxia- and radiation-inducible, breast cell-specific targeting of retroviral vectors

Virology

Volumn 349, Issue 1, 2006, Pages 121-133

  Lipnik, Karoline ^a   Greco, Olga ^b   Scott, Simon ^c   Knapp, Elzbieta ^a   Mayrhofer, Elisabeth ^a   Rosenfellner, Doris ^a   Günzburg, Walter H ^a   Salmons, Brian ^d   Hohenadl, Christine ^a,d  

^a UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d Austrianova Biomanufacturing Company   (Austria)

Author keywords

Breast cancer xenografts; Breast cell specific expression targeting; CArG element; Hypoxia responsive element; Mouse model; Promoter conversion; Retroviral vector

Indexed keywords

ACID PROTEIN; PROTEIN WAP; RETROVIRUS VECTOR; UNCLASSIFIED DRUG;

ARTICLE; BREAST ADENOCARCINOMA; BREAST CELL; CANCER CELL; CANCER CELL DESTRUCTION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CONTROLLED STUDY; ENHANCER REGION; GENE EXPRESSION; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IONIZING RADIATION; PRIORITY JOURNAL; REPORTER GENE; SCID MOUSE; SOLID TUMOR; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; XENOGRAFT;

ANIMALS; BREAST NEOPLASMS; CELL HYPOXIA; CELL LINE; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; GENE THERAPY; GENES, REPORTER; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, SCID; MICROSCOPY, FLUORESCENCE; MILK PROTEINS; NEOPLASM TRANSPLANTATION; PROMOTER REGIONS (GENETICS); RETROVIRIDAE; SENSITIVITY AND SPECIFICITY; TRANSPLANTATION, HETEROLOGOUS; X-RAYS;

MURINAE;

EID: 33646517273     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2005.12.038     Document Type: Article

References (53)

1. Azuma C., Raleigh J.A., and Thrall D.E. Longevity of pimonidazole adducts in spontaneous canine tumors as an estimate of hypoxic cell lifetime. Radiat. Res. 148 (1997) 35-42
2. Blohmer J.U., Dunst J., Harrison L., Johnston P., Khayat D., Ludwig H., O'Brien M., Van Belle S., and Vaupel P. Cancer-related anemia: biological findings, clinical implications and impact on quality of life. Oncology 68 (2005) 12-21
3. Brizel D.M., Scully S.P., Harrelson J.M., Layfield L.J., Bean J.M., Prosnitz L.R., and Dewhirst M.W. Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. Cancer Res. 56 (1996) 941-943
4. Brown J.M., and Wilson W.R. Exploiting tumour hypoxia in cancer treatment. Nat. Rev., Cancer 4 (2004) 437-447
5. Cowen R.L., Williams K.J., Chinje E.C., Jaffar M., Sheppard F.C., Telfer B.A., Wind N.S., and Stratford I.J. Hypoxia targeted gene therapy to increase the efficacy of tirapazamine as an adjuvant to radiotherapy: reversing tumor radioresistance and effecting cure. Cancer Res. 64 (2004) 1396-1402
6. Dales J.P., Garcia S., Meunier-Carpentier S., Andrac-Meyer L., Haddad O., Lavaut M.N., Allasia C., Bonnier P., and Charpin C. Overexpression of hypoxia-inducible factor HIF-1alpha predicts early relapse in breast cancer: retrospective study in a series of 745 patients. Int. J. Cancer 116 (2005) 734-739
7. Datta R., Rubin E., Sukhatme V., Qureshi S., Hallahan D., Weichselbaum R.R., and Kufe D.W. Ionizing radiation activates transcription of the EGR1 gene via CArG elements. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 10149-10153
8. Denko N.C., Fontana L.A., Hudson K.M., Sutphin P.D., Raychaudhuri S., Altman R., and Giaccia A.J. Investigating hypoxic tumor physiology through gene expression patterns. Oncogene 22 (2003) 5907-5914
9. De Schutter H., Landuyt W., Verbeken E., Goethals L., Hermans R., and Nuyts S. The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy ± chemotherapy. BMC Cancer 5 (2005) 42
10. Dorie M.J., and Kallman R.F. Reoxygenation in the RIF-1 tumor after chemotherapy. Int. J. Radiat. Oncol. Biol. Phys. 24 (1992) 295-299
11. Fyles A.W., Milosevic M., Wong R., Kavanagh M.C., Pintilie M., Sun A., Chapman W., Levin W., Manchul L., Keane T.J., and Hill R.P. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother. Oncol. 48 (1998) 149-156
12. Fyles A., Milosevic M., Hedley D., Pintilie M., Levin W., Manchul L., and Hill R.P. Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. J. Clin. Oncol. 20 (2002) 680-687
13. Greco O., Marples B., Dachs G.U., Williams K.J., Patterson A.V., and Scott S.D. Novel chimeric gene promoters responsive to hypoxia and ionizing radiation. Gene Ther. 9 (2002) 1403-1411
14. Greco O., Marples B., Joiner M.C., and Scott S.D. How to overcome (and exploit) tumor hypoxia for targeted gene therapy. J. Cell. Physiol. 197 (2003) 312-325
15. Greco O., Marples B., Wilson G.D., Joiner M.C., and Scott S.D. Radiation-induced gene therapy. Radiat. Res. 163 (2005) 707-708
16. Hallahan D.E., Mauceri H.J., Seung L.P., Dunphy E.J., Wayne J.D., Hanna N.N., Toledano A., Hellman S., Kufe D.W., and Weichselbaum R.R. Spatial and temporal control of gene therapy using ionizing radiation. Nat. Med. 1 (1995) 786-791
17. Harrison L., and Blackwell K. Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy?. Oncologist 9 Suppl 5 (2004) 31-40
18. Hasan N.M., Adams G.E., Joiner M.C., Marshall J.F., and Hart I.R. Hypoxia facilitates tumour cell detachment by reducing expression of surface adhesion molecules and adhesion to extracellular matrices without loss of cell viability. Br. J. Cancer 77 (1998) 1799-1805
19. Hlavaty J., Stracke A., Klein D., Salmons B., Günzburg W.H., and Renner M. Multiple modifications allow high-titer production of retroviral vectors carrying heterologous regulatory elements. J. Virol. 78 (2004) 1384-1392
20. Hockel M., Schlenger K., Aral B., Mitze M., Schaffer U., and Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res. 56 (1996) 4509-4515
21. Ido A., Uto H., Moriuchi A., Nagata K., Onaga Y., Onaga M., Hori T., Hirono S., Hayashi K., Tamaoki T., and Tsubouchi H. Gene therapy targeting for hepatocellular carcinoma: selective and enhanced suicide gene expression regulated by a hypoxia-inducible enhancer linked to a human alpha-fetoprotein promoter. Cancer Res. 61 (2001) 3016-3021
22. Kimura H., Braun R.D., Ong E.T., Hsu R., Secomb T.W., Papahadjopoulos D., Hong K., and Dewhirst M.W. Fluctuations in red cell flux in tumor microvessels can lead to transient hypoxia and reoxygenation in tumor parenchyma. Cancer Res. 56 (1996) 5522-5528
23. Klein D., Bugl B., Günzburg W.H., and Salmons B. Accurate estimation of transduction efficiency necessitates a multiplex real-time PCR. Gene Ther. 7 (2000) 458-463
24. Klein D., Leutenegger C.M., Bahula C., Gold P., Hofmann-Lehmann R., Salmons B., Lutz H., and Günzburg W.H. Influence of preassay and sequence variations on viral load determination by a multiplex real-time reverse transcriptase-polymerase chain reaction for feline immunodeficiency virus. J. Acquired Immune Defic. Syndr. 26 (2001) 8-20
25. Lin C.Q., Dempsey P.J., Coffey R.J., and Bissell M.J. Extracellular matrix regulates whey acidic protein gene expression by suppression of TGF-alpha in mouse mammary epithelial cells: studies in culture and in transgenic mice. J. Cell Biol. 129 (1995) 1115-1126
26. Lipnik K., Petznek H., Renner-Muller I., Egerbacher M., Url A., Salmons B., Günzburg W.H., and Hohenadl C. A 470 bp WAP-promoter fragment confers lactation independent, progesterone regulated mammary-specific gene expression in transgenic mice. Transgenic Res. 14 (2005) 145-158
27. Marples B., Scott S.D., Hendry J.H., Embleton M.J., Lashford L.S., and Margison G.P. Development of synthetic promoters for radiation-mediated gene therapy. Gene Ther. 7 (2000) 511-517
28. Minchenko O.H., Opentanova I.L., Ogura T., Minchenko D.O., Komisarenko S.V., Caro J., and Esumi H. Expression and hypoxia-responsiveness of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 4 in mammary gland malignant cell lines. Acta Biochim. Pol. 52 (2005) 881-888
29. Mrochen S., Klein D., Nikol S., Smith J.R., Salmons B., and Günzburg W.H. Inducible expression of p21WAF-1/CIP-1/SDI-1 from a promoter conversion retroviral vector. J. Mol. Med. 75 (1997) 820-828
30. Neubauer J.A. Invited review: physiological and pathophysiological responses to intermittent hypoxia. J. Appl. Physiol. 90 (2001) 1593-1599
31. Niizeki H., Kobayashi M., Horiuchi I., Akakura N., Chen J., Wang J., Hamada J.I., Seth P., Katoh H., Watanabe H., Raz A., and Hosokawa M. Hypoxia enhances the expression of autocrine motility factor and the motility of human pancreatic cancer cells. Br. J. Cancer 86 (2002) 1914-1919
32. Nordsmark M., Alsner J., Keller J., Nielsen O.S., Jensen O.M., Horsman M.R., and Overgaard J. Hypoxia in human soft tissue sarcomas: adverse impact on survival and no association with p53 mutations. Br. J. Cancer 84 (2001) 1070-1075
33. Öztürk-Winder F., Renner M., Klein D., Muller M., Salmons B., and Günzburg W.H. The murine whey acidic protein promoter directs expression to human mammary tumors after retroviral transduction. Cancer Gene Ther. 9 (2002) 421-431
34. Pambalk K., Hohenadl C., Salmons B., Günzburg W.H., and Renner M. Specific packaging of spliced retroviral vector transcripts lacking the Psi-region. Biochem. Biophys. Res. Commun. 293 (2002) 239-246
35. Park J.O., Lopez C.A., Gupta V.K., Brown C.K., Mauceri H.J., Darga T.E., Manan A., Hellman S., Posner M.C., Kufe D.W., and Weichselbaum R.R. Transcriptional control of viral gene therapy by cisplatin. J. Clin. Invest. 110 (2002) 403-410
36. Rofstad E.K., Rasmussen H., Galappathi K., Mathiesen B., Nilsen K., and Graff B.A. Hypoxia promotes lymph node metastasis in human melanoma xenografts by up-regulating the urokinase-type plasminogen activator receptor. Cancer Res. 62 (2002) 1847-1853
37. Rofstad E.K., Mathiesen B., and Galappathi K. Increased metastatic dissemination in human melanoma xenografts after subcurative radiation treatment: radiation-induced increase in fraction of hypoxic cells and hypoxia-induced up-regulation of urokinase-type plasminogen activator receptor. Cancer Res. 64 (2004) 13-18
38. Roland I., Minet E., Ernest I., Pascal T., Michel G., Remacle J., and Michiels C. Identification of hypoxia-responsive messengers expressed in human microvascular endothelial cells using differential display RT-PCR. Eur. J. Biochem. 267 (2000) 3567-3574
39. Saller R.M., Öztürk F., Salmons B., and Günzburg W.H. Construction and characterization of a hybrid mouse mammary tumor virus/murine leukemia virus-based retroviral vector. J. Virol. 72 (1998) 1699-1703
40. Scott S.D., and Greco O. Radiation and hypoxia inducible gene therapy systems. Cancer Metastasis Rev. 23 (2004) 269-276
41. Scott S.D., and Marples B. Radiation-activated antitumor vectors. Methods Mol. Med. 90 (2004) 389-402
42. Scott S.D., Marples B., Hendry J.H., Lashford L.S., Embleton M.J., Hunter R.D., Howell A., and Margison G.P. A radiation-controlled molecular switch for use in gene therapy of cancer. Gene Ther. 7 (2000) 1121-1125
43. Semenza G.L., and Wang G.L. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol. Cell. Biol. 12 (1992) 5447-5454
44. Shimizu S., Eguchi Y., Kosaka H., Kamiike W., Matsuda H., and Tsujimoto Y. Prevention of hypoxia-induced cell death by Bcl-2 and Bcl-xL. Nature 374 (1995) 811-813
45. Su H., Joho S., Huang Y., Barcena A., Arakawa-Hoyt J., Grossman W., and Kan Y.W. Adeno-associated viral vector delivers cardiac-specific and hypoxia-inducible VEGF expression in ischemic mouse hearts. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 16280-16285
46. To K.K., Koshiji M., Hammer S., and Huang L.E. Genetic instability: the dark side of the hypoxic response. Cell Cycle 4 (2005) 7
47. Truong P.T., Olivotto I.A., Whelan T.J., and Levine M. Clinical practice guidelines for the care and treatment of breast cancer: 16. Locoregional post-mastectomy radiotherapy. CMAJ 170 (2004) 1263-1273
48. Vaupel P., and Mayer A. Hypoxia and anemia: effects on tumor biology and treatment resistance. Transfus. Clin. Biol. 12 (2005) 5-10
49. Vaupel P., Schlenger K., Knoop C., and Hockel M. Oxygenation of human tumors: evaluation of tissue oxygen distribution in breast cancers by computerized O2 tension measurements. Cancer Res. 51 (1991) 3316-3322
50. Vengellur A., Phillips J.M., Hogenesch J.B., and LaPres J.J. Gene expression profiling of hypoxia signaling in human hepatocellular carcinoma cells. Physiol. Genomics 22 (2005) 308-318
51. Wang D., Ruan H., Hu L., Lamborn K.R., Kong E.L., Rehemtulla A., and Deen D.F. Development of a hypoxia-inducible cytosine deaminase expression vector for gene-directed prodrug cancer therapy. Cancer Gene Ther. 12 (2005) 276-283
52. Whelan T., MacKenzie R., Julian J., Levine M., Shelley W., Grimard L., Lada B., Lukka H., Perera F., Fyles A., Laukkanen E., Gulavita S., Benk V., and Szechtman B. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer. J. Natl. Cancer Inst. 94 (2002) 1143-1150
53. Zhou J., Schmid T., Schnitzer S., and Brune B. Tumor hypoxia and cancer progression. Cancer Lett. 4 (2005) 4